Jing Du

Since joining Kirkland & Ellis, Jing's representative experience includes:

• Represented the joint sponsors, UBS Securities Hong Kong Limited, China International Capital Corporation Hong Kong, Ping An of China Capital (Hong Kong) Company Limited and GF Capital (Hong Kong) Limited, and underwriters on the HK$4.8 billion global offering and listing of OmniVision Integrated Circuits Group, Inc. (SH: 603501; HKSE: 0501), a global fabless semiconductor design company, on the Main Board of the Hong Kong Stock Exchange
• Represented Suzhou Ribo Life Science Co., Ltd. (HKSE: 6938) on its global offering and listing on the Hong Kong Stock Exchange. The IPO raised approximately HK$1.83 billion after the full exercise of Offer Size Adjustment Option. Ribo Life is a leading biopharmaceutical company specializing in siRNA therapeutics
• Represented Goldman Sachs (Asia) L.L.C. and Citigroup Global Markets Limited, in connection with the H-share placing of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd on June 12, 2025. The net proceeds from the H-Share Placing amounted to approximately HKD 1.943 billion (USD 250 million)
• Represented Contemporary Amperex Technology Co., Limited (CATL) on its global offering and listing on the Hong Kong Stock Exchange. The IPO raised approximately HK$41 billion (US$5.3 billion) after the exercise of the over-allotment option. CATL is a global leader in new energy innovative technologies, primarily engaged in the research, development, production, and sales of EV and ESS batteries. This transaction was named “Best Equity Deal (APAC and Hong Kong)” and "Highly commended Best IPO (Hong Kong)" by FinanceAsia Achievement Awards 2025.
• Represented Duality Biotherapeutics (HKEx: 9606) on its global offering and listing on the Main Board of the Hong Kong Stock Exchange. The IPO raised approximately HK$1.64 billion prior to the exercise of the over-allotment option
• Represented NIO Inc. (NYSE: NIO; HKEx: 9866; SGX: NIO) in connection with its HK$4,030.13 million offering of 136,800,000 class A ordinary shares. This transaction was named the “Most Innovative Deal (Hong Kong)” by FinanceAsia Achievement Awards 2025.
• Represented the joint sponsors and underwriters on the global offering and listing of Dida Inc. (HKSE: 02559) on The Stock Exchange of Hong Kong Limited on June 28, 2024. China International Capital Corporation Hong Kong Securities Limited, Haitong International Capital Limited and Nomura International (Hong Kong) Limited acted as the joint sponsors for this transaction
• Represented the underwriters in the initial public offering and listing of BingEx Limited, a leading independent on-demand courier service provider in China, on the Nasdaq Stock Market under the symbol “FLX”
• Represented Canaan Inc. (Nasdaq: CAN) in Series A-1 preferred shares financing
• Represented Tims China (Nasdaq: THCH), Canadian Solar (Nasdaq: CSIQ), Fanhua Inc. (Nasdaq:FANH) and MoneyHero Limited (Nasdaq: MNY) in their post-U.S. listing compliance matters
• Represented Goldman Sachs (Asia) L.L.C., Citigroup Global Markets Limited and J.P. Morgan Securities (Asia Pacific) Limited, in connection with the H-share placing of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. The net proceeds from the H-Share Placing amounted to approximately HK$541.4 million
• Represented Will Semiconductor Co., Ltd. Shanghai (SHA: 603501), a global leading fabless semiconductor company, in its US$445 million offering of 31,000,000 global depositary receipts. This transaction marked the largest offshore listing by a China-based semiconductor company since 2005. This transaction was named “Deals of the Year 2023” by China Business Law Journal
• Represented ZX Inc. (HKSE: 9890), a leading online game products publisher in China, on its global offering and listing on the Hong Kong Exchanges and Clearing Limited on September 28, 2023
• Represented the joint sponsors and underwriters on the global offering and listing of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKSE: 1541), a leading science-driven biotechnology company dedicated to the development of immuno-oncology therapies in China, on the Hong Kong Exchanges and Clearing Limited on September 5, 2023
• Represented Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKSE: 6990) on its US$174 million global offering and listing on the Stock Exchange of Hong Kong Limited on July 11, 2023 This transaction was named “Best IPO - Hong Kong SAR” by FinanceAsia Achievement Awards 2023

Prior to joining Kirkland & Ellis, Jing's representative experience includes:

• Represented Morgan Stanley, CICC and Credit Suisse as the joint sponsors in the US$281 million global offering and listing of SciClone Pharmaceuticals (HKSE: 6600), a China-focused biopharmaceutical company specializing in oncology and severe infection, on the Main Board of the Hong Kong Stock Exchange
• Represented Morgan Stanley and CICC as the joint sponsors in the US$394.5 million global offering and listing of Cheerwin Group Limited (HKSE: 6601), a leading multi-category household care and personal care platform in China, on the Main Board of The Hong Kong Stock Exchange
• Represented China Bohai Bank (HKSE: 9668), a national joint-stock commercial bank in China, in its US$1.77 billion global offering and listing of its H shares on the Main Board of the Hong Kong Stock Exchange
• Represented Credit Suisse, Morgan Stanley, and ICBC International Capital as the joint sponsors in the US$381 million global offering and listing of JS Global Lifestyle (HKSE: 1691), a global leader in innovative small household appliances, on the Main Board of The Hong Kong Stock Exchange
• Represented Jinshang Bank (HKSE: 2558), the only provincial city commercial bank in Shanxi Province, in its US$422 million global offering and listing of its H shares on the Main Board of the Hong Kong Stock Exchange